ZVRA · Zevra Therapeutics, Inc.

Current Thesis

Zevra Therapeutics’ recovery rests on continued US MIPLYFFA growth: Q3 revenue above Q2’s $30.2 million would confirm the commercial leg, while a weekly close below $11.50 would invalidate the reclaimed-base thesis. The 2026-09-11 reference close of $12.01 exceeds the 2026-07-24 session high of $11.59, advancing the structure beyond the resistance described in the 2026-08-30 assessment. That is a measured price improvement; durable support remains an inference.

The narrative is maturing — the commercial results published on 2026-08-05 now underpin another conference cycle announced on 2026-09-02, while the shares’ three-month price change remained negative at 5.1% on 2026-09-11. This classification describes the sequence of disclosures and price performance; it does not establish investor participation. The European opportunity remains conditional following the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) negative opinion announced on 2026-07-24. Zevra regulatory update

Bullish and bearish views on Zevra Therapeutics, Inc.

The model's bull view on Zevra Therapeutics, Inc. (ZVRA), in brief: Commercial revenue supports the recovery. The bear view: Revenue includes expanded-access reimbursements. Both cases follow in full.

Bull Case

• Commercial revenue supports the recovery. Zevra’s 2026-08-05 results reported Q2 MIPLYFFA net revenue of $30.2 million and total net revenue of $39.7 million. These establish the commercial benchmark for the next report. Q2 results
• Liquidity accompanies reported profitability. The same release reported $260.2 million of company cash, equivalents and investments at 2026-06-30 and Q2 net income of $8.8 million. These are reported financial resources and earnings, rather than evidence that European approval is probable. Q2 results

Bear Case

• Revenue includes expanded-access reimbursements. Q2 revenue included $9.0 million from the global Expanded Access Program, according to the 2026-08-05 release. Total revenue therefore cannot substitute for measuring commercial MIPLYFFA growth. Q2 results
• Enrollment needs a longer record. At 2026-06-30, cumulative prescription enrollment forms numbered 184, including 14 received during Q2; payer coverage was 69% of covered lives. One quarter of enrollment additions cannot establish either acceleration or patient-pool saturation. Q2 results
• Re-examination leaves approval unresolved. Zevra announced the negative CHMP opinion on 2026-07-24 and confirmed a re-examination request in its 2026-08-05 update. A request is a procedural development, not a reversal of the opinion. Regulatory announcement, Q2 update

Setup & Price Structure

The adjusted reference close was $12.01 on 2026-09-11, with the shares 18.6% below the supplied 52-week high of $14.75. The 14-period relative strength index (RSI) was 52.1. The close above the July rejection session’s $11.59 high removes the earlier description of price remaining capped beneath that level; it does not establish a sustained breakout.

The $11.50 pre-rejection base identified in the July price record is the research boundary for this narrower recovery thesis. A weekly close below $11.50 would show that the reclaimed structure failed.

The observable attention cluster is management’s scheduled appearances on 2026-09-09, 2026-09-14 and 2026-09-15, announced on 2026-09-02. Conference scheduling establishes exposure opportunities; it supplies no measurement of retail enthusiasm, institutional demand or crowded ownership. No current moving-average series or ownership-flow measurements accompany the 2026-09-11 snapshot. Conference announcement

Catalyst Calendar (next 30 days)

The previously published ~2026-09-22 re-examination-grounds date remains an unconfirmed procedural estimate and is not treated as a decision date. Beyond the next month, ~2026-11-05 remains the prior public calendar’s estimate for Q3 results, not a company-confirmed appointment. That report is the commercial test on which this thesis turns.

Elapsed catalysts

• 2026-09-14 — Morgan Stanley healthcare conference. Zevra scheduled a management fireside chat in its 2026-09-02 announcement. Any substantive disclosure can update the commercial or regulatory case; attendance itself supplies neither revenue confirmation nor an approval decision. Company schedule (passed 6d ago)
• 2026-09-15 — H.C. Wainwright investment conference. The same announcement schedules another management fireside chat. This is a confirmed communication date, with no company-promised regulatory outcome attached. Company schedule (passed 5d ago)

What Would Change Our Mind

Loss of the reclaimed July base would end the price-recovery case: a weekly close below $11.50 is the observable boundary. Commercial confirmation requires Q3 MIPLYFFA net revenue above the $30.2 million reported for Q2 on 2026-08-05 before that boundary is breached. Q3 revenue at or below that benchmark would instead reject the sequential-growth premise.

The European component requires an actual change in the CHMP opinion announced on 2026-07-24. A reaffirmed negative opinion would eliminate the regulatory-reversal component without, by itself, proving that US commercial revenue is contracting.

Correlation Notes

This is a single-company recovery and regulatory setup. The 2026-07-24 CHMP opinion and 2026-08-05 commercial results provide identifiable company events; the available record contains no paired sector-return series establishing how much of the recovery came from a broader biotechnology move. The sample is too small to support a correlation claim, and no group advance is assumed in the thesis.